Detalhe da pesquisa
1.
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Lancet Oncol
; 16(13): 1389-98, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-26433819
2.
Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients.
Breast Cancer Res Treat
; 142(2): 381-8, 2013 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-24166282
3.
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.
J Clin Oncol
; 34(8): 871-8, 2016 Mar 10.
Artigo
Inglês
| MEDLINE | ID: mdl-26811525